Co-morbidity of depression and anxiety in common age-related eye diseases: a population-based study of 662 adults

Abstract

This study examined the prevalence of co-morbid age-related eye disease and symptoms of depression and anxiety in late life, and the relative roles of visual function and disease in explaining symptoms of depression and anxiety. A community-based sample of 662 individuals aged over 70 years was recruited through the electoral roll. Vision was measured using a battery of tests including high and low contrast visual acuity, contrast sensitivity, motion sensitivity, stereoacuity, Useful Field of View, and visual fields. Depression and anxiety symptoms were measured using the Goldberg scales. The prevalence of self-reported eye disease [cataract, glaucoma, or age-related macular degeneration (AMD)] in the sample was 43.4%, with 7.7% reporting more than one form of ocular pathology. Of those with no eye disease, 3.7% had clinically significant depressive symptoms. This rate was 6.7% among cataract patients, 4.3% among those with glaucoma, and 10.5% for AMD. Generalized linear models adjusting for demographics, general health, treatment, and disability examined self-reported eye disease and visual function as correlates of depression and anxiety. Depressive symptoms were associated with cataract only, AMD, comorbid eye diseases and reduced low contrast visual acuity. Anxiety was significantly associated with self-reported cataract, and reduced low contrast visual acuity, motion sensitivity and contrast sensitivity. We found no evidence for elevated rates of depressive or anxiety symptoms associated with self-reported glaucoma. The results support previous findings of high rates of depression and anxiety in cataract and AMD, and in addition show that mood and anxiety are associated with objective measures of visual function independently of self-reported eye disease. The findings have implications for the assessment and treatment of mental health in the context of late-life visual impairment.

The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress

“…AMD is generally afflicts people over the age of 60-years-old, and is the leading cause of vision loss among the elderly (Jager et al, 2008; Eramudugolla et al, 2013). Risk factors of AMD are various and include aging and different genetic predispositions, together with several environmental/epigenetic factors, such as, cigarette smoking, dietary habits, and phototoxic exposure (Nowak, 2006; Shahid et al, 2012; Stanton and Wright, 2014).…”

Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease

“…28 Those rates are even higher in elderly patients with vision loss, especially those with cataract and AMD. 29 Vision loss and associated depression lead to decreased social engagement among the elderly. In one study of visually impaired elderly patients, minimal visual impairment (defined by the authors to include patients able to read large but not regular sized print at close range) was associated with a 19% greater prevalence of low social engagement, with rates higher than 50% in those with severe vision loss.…”

Glaucoma, Depression and Quality of Life: Multiple Comorbidities, Multiple Assessments and Multidisciplinary Plan Treatment

“…In general, patients with visual impairment have higher prevalence of psychological disturbance -such as depression, anxiety or sleep disorders (Agorastos et Spinelli et al 1998). The level of depressive symptoms is higher in patients with multiple eye disease (Eramudugolla et al 2013, Pop-Jordanova et al 2014). Dual sensory loss, such as visual and hearing impairment, increases even more the level of depressive symptoms (Kiely et al 2013).…”

“…Glaucoma firstly affects peripheral vision and secondly central vision. Since it is silent, chronic disease with no clinical signs at the beginning of illness, it is often undiagnosed and underestimated (Eramudugolla et al 2013). In many cases when diagnosed, glaucoma is already in advanced stage.…”